Drugs / Allogenic MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02336646 | May 2015 → Apr 2018 | limb ischemia | Taiwan Bio Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogenic MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02336646 ↗ |
| Modality | Cell therapy | “allogenic mesenchymal stem cells (MSCs)” NCT02336646 ↗ |
| Route | Intramuscular | “with IM injection” NCT02336646 ↗ |